Her notes focus on TRIUMPH-2, the trial in people with obesity or overweight and type 2 diabetes. The full thread is at the link.
Recap by typeshit. Post by Jen Can NuSH on X.
The candidate blocks a signal behind appetite loss and high energy burn in cancer cachexia, where patients waste away even while eating.
The new preprint looks at whether symptom relief people report on GLP-1 medications comes from weight loss alone or something else.
Lilly says participants lost 44 to 47 pounds versus about 21 on Ozempic, with bigger A1C drops. It plans to file for approval in 2027.
Lilly reports people on retatrutide lost 44 to 47 pounds over 80 weeks versus about 21 on Ozempic. It plans to file for approval in 2027.
Nadolsky calls retatrutide the most powerful medicine likely to be approved soon for weight and type 2 diabetes, in his view.
Mounjaro and Zepbound still carry Lilly, but neuroscience sales rose 32% in the first half of 2026. Lilly reports third-quarter results on Oct. 29.
Loading…